Professor, Medicine, UCSD School of Medicine
Internal Medicine
Dr. Robert J. Parmer, MD
|
|
Give Review
Robert J. Parmer is an expert in the field of Internal Medicine. He researched medicine at University of California San Diego School of Medicine. University of California San Diego School of Medicine is ranked 17 in research and 19 in primary care medicine He received awards:"Fellow (ASNF)". Robert Parmer is a published doctor and has 101 publications published. The lastest was: 'Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotin...' He is registered with Medicare and accepts Medicare payments.
Publications
- Peptidergic regulation of plasminogen activator inhibitor-1 gene expression in vivo.
- Plasminogen receptors.
- The Plasminogen Receptor, Plg-R(KT), and Macrophage Function.
- The novel plasminogen receptor, Plg-RKT, regulates macrophage migration.
- The novel plasminogen receptor, plasminogen receptorKT (Plg-RKT), regulates catecholamine release.
- Monoclonal antibodies detect receptor-induced binding sites (RIBS) in glu-plasminogen.
- The anti-fibrinolytic serpin, plasminogen activator inhibitor 1 (PAI-1), is targeted to and released from catecholamine storage vesicles.
- S100A10: a complex inflammatory role.
- PAI-1: cardiac friend or foe?
- Proteomics-based discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen ...
- Plasminogen enhances neuritogenesis on laminin-1.
- Cell-surface actin binds plasminogen and modulates neurotransmitter release from catecholaminergic cells.
- Genetic variation at the human alpha2B-adrenergic receptor locus: role in blood pressure variation and yohimbine response.
- Plasminogen receptors: the sine qua non of cell surface plasminogen activation.
- Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug Metabolism.
- Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catest...
- Diminished Renal kallikrein responses to mineralocorticoid stimulation in African Americans: determinants of an intermediate phenotype for hypertension.
- Localization of regulatory elements mediating constitutive and cytokine-stimulated plasminogen gene expression.
- The local chromaffin cell plasminogen/plasmin system and the regulation of catecholamine secretion.
- The catecholamine release-inhibitory "catestatin" region of chromogranin a: early decline in humans at genetic risk of Hypertension.
- Catecholaminergic pathways, chromaffin cells, and human Disease.
- Intracellular protein trafficking into catecholamine storage vesicles: novel chimeric photoproteins visualized by deconvolution fluorescence microscopy.
- Chromaffin cell plasminogen receptors.
- Identification of a novel sorting determinant for the regulated pathway in the secretory protein chromogranin A.
- Plasminogen has a broad extrahepatic distribution.
- Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of Hypertension.
- Early alteration in glomerular reserve in humans at genetic risk of essential Hypertension: mechanisms and consequences.
- Proteolytic cleavage of chromogranin A (CgA) by plasmin. Selective liberation of a specific bioactive CgA fragment that regulates catecholamine release.
- Beta2-adrenergic receptor polymorphisms at codon 16, cardiovascular phenotypes and essential Hypertension in whites and African Americans.
- Circulating amylin in human essential Hypertension: heritability and early increase in individuals at genetic risk.
- Stimulus-transcription coupling in pheochromocytoma cells. Promoter region-specific activation of chromogranin a biosynthesis.
- Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. Catecholamine storage vesicles as a reservoir for the rapid release of t-PA.
- Regulation of plasminogen gene expression by interleukin-6.
- Expression of altered alpha2-adrenergic phenotypic traits in normotensive humans at genetic risk of hereditary (essential) Hypertension.
- Desensitization of catecholamine release. The novel catecholamine release-inhibitory peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotin...
- Catecholamine secretory vesicles. Augmented chromogranins and amines in secondary Hypertension.
- Vesicular monoamine transport inhibitors. Novel action at Calcium channels to prevent catecholamine secretion.
- Arterial compliance by cuff sphygmomanometer. Application to Hypertension and early changes in subjects at genetic risk.
- Chromogranin A in human Hypertension. Influence of heredity.
- Molecular cloning of chromogranin A from rat pheochromocytoma cells.
- Structure and function of the chromogranin A gene. Clues to evolution and tissue-specific expression.
- Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist.
- A novel, catecholamine release-inhibitory peptide from chromogranin A: autocrine control of nicotinic cholinergic-stimulated exocytosis.
- Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules.
- Catecholamine storage vesicle protein expression in genetic Hypertension.
- Binding of human single chain urokinase to Chinese Hamster Ovary cells and cloning of hamster u-PAR.
- Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a beta-strand/loop/beta-strand structure secured by...
- Proadrenomedullin N-terminal 20 peptide: minimal active region to regulate nicotinic receptors.
- Processing of chromogranin A by plasmin provides a novel mechanism for regulating catecholamine secretion.
- Interaction of the catecholamine release-inhibitory peptide catestatin (human chromogranin A(352-372)) With the chromaffin cell surface and Torpedo electroplax: implic...
- Renal kallikrein excretion: role of ethnicity, gender, environment, and genetic risk of hypertension.
- Tissue plasminogen activator and chromaffin cell function.
- The novel catecholamine release-inhibitory peptide catestatin (chromogranin A344-364). Properties and function.
- Interleukin-6-induced plasminogen gene expression in murine hepatocytes is mediated by transcription factor CCAAT/enhancer binding protein beta (C/EBPbeta).
- Plasminogen gene expression is regulated by nerve growth factor.
- Glucocorticoid activation of chromogranin A gene expression. Identification and characterization of a novel glucocorticoid response element.
- A functional cyclic AMP response element plays a crucial role in neuroendocrine cell type-specific expression of the secretory granule protein chromogranin A.
- Divergent effects of dihydropyridine and phenylalkylamine Calcium channel antagonist classes on autonomic function in human hypertension.
- Enkephalins in human phaeochromocytomas: localization in immunoreactive, high molecular weight form to the soluble core of chromaffin granules.
- Sympatho-adRenal secretion in humans: factors governing catecholamine and storage vesicle peptide co-release.
- Plasma hydrogen peroxide production in human essential Hypertension: role of heredity, gender, and ethnicity.
- Neurotrophin activation of catecholamine storage vesicle protein gene expression: signaling to chromogranin a biosynthesis.
- Factitious pheochromocytoma: novel mimickry by Valsalva maneuver and clues to diagnosis.
- Does lipophilicity of angiotensin converting enzyme inhibitors selectively influence autonomic neural function in human Hypertension?
- Is physiologic sympathoadRenal catecholamine release exocytotic in humans?
- Variability in phenylephrine response and essential Hypertension: a search for human alpha(1B)-adrenergic receptor polymorphisms.
- Hereditary intermediate phenotypes in African American Hypertension.
- Chromogranin A processing and secretion: specific role of endogenous and exogenous prohormone convertases in the regulated secretory pathway.
- Racial differences in Renal kallikrein excretion: effect of the ovulatory cycle.
- Effects of an oral prostaglandin E1 agonist on blood pressure and its determinants in essential Hypertension.
- Suppression of chromogranin-A release from neuroendocrine sources in man: pharmacological studies.
- Assignment of the chromogranin A (Chga) locus to homologous regions on mouse chromosome 12 and rat chromosome 6.
- Chromogranin A. Storage and release in Hypertension.
- Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution.
- Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma.
- Renal hemodynamics in essential hypertension. Racial differences in response to changes in dietary sodium.
- Stimulus coupling to transcription versus secretion in pheochromocytoma cells. Convergent and divergent signal transduction pathways and the crucial roles for route of...
- Chromogranin A in human Disease.
- Heredity and the autonomic nervous system in human Hypertension.
- Physical mapping of autonomic/sympathetic candidate genetic loci for Hypertension in the human genome: a somatic cell radiation hybrid library approach.
- Processing of chromaffin granule proteins: a profusion of proteases?
- Secretory protein traffic. Chromogranin A contains a dominant targeting signal for the regulated pathway.
- A cloned chromogranin A (CgA) cDNA detects a 2.3Kb mRNA in diverse neuroendocrine tissues.
- Molecular genetics of essential Hypertension: recent results and emerging strategies.
- Chromogranin A in the olfactory system of the rat.
- Plasma epinephrine levels in Hypertension and across gender and ethnicity.
- Dopamine beta-hydroxylase immunoreactivity in human cerebrospinal fluid: properties, relationship to central noradrenergic neuronal activity and variation in Parkinson...
- Circulating chromogranin A as a diagnostic tool in clinical chemistry.
- Autonomic function in Hypertension. Are there racial differences?
- Chromogranin A immunoreactivity in human cerebrospinal fluid: properties, relationship to noradrenergic neuronal activity, and variation in neurologic Disease.
- Plasma chromogranin A: a marker of serotonin release and of emesis associated With cisplatin chemotherapy.
- Plasma chromogranin A marks emesis and serotonin release associated With dacarbazine and nitrogen mustard but not With cyclophosphamide-based chemotherapies.
- Targeting of tissue plasminogen activator to the regulated pathway of secretion.
- Molecular cloning, structure, and expression of dopamine-beta-hydroxylase from bovine adRenal medulla.
- Chromogranin A: studies in the endocrine system.
- Serum zinc is unaffected by effective captopril treatment of Hypertension.
- Enkephalins in pheochromocytoma: studies in a rat model.
- Complex trait genetics: new methods yield a result for essential Hypertension.
- Activities of nitric oxide in normal physiology and uremia.
- Baroreflex sensitivity and heredity in essential Hypertension.
Schools
University Of California San Diego School Of Medicine
University Ca San Diego Med Center
Conditions Treated
- Acute Kidney Failure
- Calcium Metabolism Disorders
- Chronic Kidney Diseases
- Congenital Cystic Kidney Disease
- View All
Doctors Specialties
- Nephrology
- Internal Medicine
Accepted Insurances
Awards
- Fellow (ASNF)
Education
-
University of California San Diego -
University of California San Diego School of Medicine
Drug Facts
| NPI NUMBER | 1013932318 | |
| NPPES Provider LastName | PARMER | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 920935004 | |
| NPPES Provider State | CA | |
| Specialty Description | Nephrology | |
| Total Claim Count | 43.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1013932318 |
| Last Name Of The Provider | PARMER |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
|
Dr. James B. Cordell, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John W. Adamson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark C. Adrian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Radha Verman, MD |
|
|
Dr. Kimberly L. Harper, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter S. Friend, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria Savoia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura J. Nicholson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William R. Auger, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Caitlin E. Carter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lalaine M. Corate, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Bijan Roshan, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mark M. Boiskin, MD
This Doctor is OpenDoctor Recommended.
|